03639045.2020.1821054 Metodo HPLC Paracetamol Imp J

Download as pdf or txt
Download as pdf or txt
You are on page 1of 29

Drug Development and Industrial Pharmacy

ISSN: 0363-9045 (Print) 1520-5762 (Online) Journal homepage: https://www.tandfonline.com/loi/iddi20

Validated Specific HPLC-DAD Method for


Simultaneous Estimation of Paracetamol and
Chlorzoxazone in Presence of Five of Their
Degradation Products and Toxic Impurities

Amira F. El-Yazbi, Karin M. Guirguis, Mona M. Bedair & Tarek S. Belal

To cite this article: Amira F. El-Yazbi, Karin M. Guirguis, Mona M. Bedair & Tarek S. Belal
(2020): Validated Specific HPLC-DAD Method for Simultaneous Estimation of Paracetamol and
Chlorzoxazone in Presence of Five of Their Degradation Products and Toxic Impurities, Drug
Development and Industrial Pharmacy, DOI: 10.1080/03639045.2020.1821054

To link to this article: https://doi.org/10.1080/03639045.2020.1821054

Accepted author version posted online: 07


Sep 2020.

Submit your article to this journal

Article views: 1

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at


https://www.tandfonline.com/action/journalInformation?journalCode=iddi20
Validated Specific HPLC-DAD Method for Simultaneous Estimation

of Paracetamol and Chlorzoxazone in Presence of Five of Their

Degradation Products and Toxic Impurities

t
ip
cr
us

Amira F. El-Yazbi 1, Karin M. Guirguis 2, Mona M. Bedair 1, Tarek S. Belal 1
an
1 Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, University of
M
Alexandria, Elmessalah, 21521, Alexandria, Egypt
d

2 Pharmaceutical Chemistry Department, Faculty of Pharmacy and Drug Manufacturing, Pharos


e

University in Alexandria, Canal El-Mahmoudia Street, Alexandria, Egypt


pt
ce
Ac


Corresponding Author: Tarek S. Belal
E-mail: [email protected]
Abstract

This work demonstrates a specific and reliable HPLC with diode array detection (DAD)

method for the simultaneous estimation of paracetamol (PAR) and chlorzoxazone (CZ) in

presence of five of their degradation products and toxic impurities; namely; 4-aminophenol (AP),

4-nitrophenol (NP), acetanilide (AT), 4-chloroacetanilide (CA) and 2-amino-4-chlorophenol

(ACP). Successful chromatographic separation was accomplished using Waters Symmetry C8

t
ip
column (3.9 × 150 mm, 5 μm) with gradient elution of the mobile phase consisting of 0.05 M

cr
phosphate buffer pH 7.5 and methanol. The gradient elution started with 5% (by volume)

methanol ramped up linearly to 50% in 10 min, and then maintained at this percentage afterwards

us
till the end of the run. The mobile phase was pumped at a flow rate of 1.0 mL/min. The multiple
an
wavelength detector was adjusted at 244 and 285 nm to quantify PAR and CZ, respectively.

Additionally, the wavelength 270 nm was found suitable for monitoring separation of the entire
M
mixture of PAR, CZ and their impurities. Seven peaks eluted with excellent resolution at
d

retention times 3.4, 5.7, 8.0, 10.1, 10.8, 13.5 and 14.4 min for AP, PAR, NP, AT, ACP, CZ and
e

CA respectively. Performance of the proposed method was validated with respect to linearity,
pt

range, precision, accuracy, specificity, robustness, detection and quantitation limits. Calibration
ce

curves were linear in the ranges of 10-75 and 10-100 g/mL for PAR and CZ, respectively with

correlation coefficients not less than 0.9998. The proposed method proved to be specific and
Ac

stability-indicating by resolution of both drugs from their degradation products and toxic

impurities. Validated HPLC method was successfully applied to the analysis of PAR and CZ in

their combined capsules dosage form, and assay results were favorably compared with a

published reference HPLC method. DAD served as an efficient tool for peak identity and purity

verification.
Keywords: Paracetamol ; Chlorzoxazone ; HPLC-DAD ; Impurities ; Degradation products.

Introduction

Paracetamol (PAR) (Figure 1) is an analgesic antipyretic drug which was introduced into

medical practice many years ago and it is still accepted as a very effective treatment for the relief

of fever and several types of pain in adults and children (1). PAR has several related substances

and potential impurities that should be considered during assay of the bulk powder and final

t
ip
dosage forms. Four pharmacopeial related substances for PAR are included in this study: 4-

cr
aminophenol (AP), 4-nitrophenol (NP), acetanilide (AT) and 4-chloroacetanilide (CA) (2,3).

Figure 1 shows the chemical structures of these related substances. AP is the main hydrolytic

us
degradation product of PAR, in addition, AP is known to be nephrotoxic and hepatotoxic (4).
an
Similarly, CA is reported to be hepatotoxic and nephrotoxic as well (5). In regard to NP, it is one

of the most toxic and serious contaminant organic pollutants, which can easily irritate eyes, skin,
M
and respiratory tract (6). On the other hand, AT was formerly used as an antipyretic drug. The use
d

of AT was shortly discontinued because some patients developed a bluish color of the skin
e

(cyanosis). This serious side effect was later identified to result from methemoglobinemia where
pt

AT interferes with the oxygen transport by hemoglobin (7). The toxicant properties of these
ce

compounds suggest that their separation and monitoring during analysis of the main drug is of

extreme importance and priority.


Ac

More focus can be found in the scientific literature for the simultaneous determination of

PAR and its main impurity AP. Methods used for this task included electrochemical

determination employing different sensors and electrodes (8-11), spectrophotometric (12, 13),

near infrared (NIR) spectroscopic (14), HPLC-DAD (15), UPLC/Q-TOF-MS (16), HPTLC (17)

and capillary electrophoresis (CE) methods (18, 19). Moreover, different chromatographic
techniques were applied for separation and determination of complex mixtures containing PAR

together with two or more of the its impurities. HPLC (5, 20, 21), UPLC (22), TLC–densitometry

(5) and GC/MS (23) were found useful for analysis of these multi-component mixtures.

Chlorzoxazone (CZ) (Figure 1) is a centrally acting skeletal muscle relaxant with sedative

properties (24). The main degradation product and a synthetic precursor of CZ is 2-amino-4-

chlorophenol (ACP) (25) (Figure 1). This compound is reported as nephrotoxic and a possible

t
carcinogenic (26, 27). Selective determination of CZ and other drugs in different pharmaceutical

ip
mixtures in presence of their degradation products was carried out using HPLC-DAD (26, 28),

cr
HPLC with UV detection (29, 30) and TLC methods (26, 28, 31).

us
Combination therapy is commonly used for management of different musculoskeletal
an
painful conditions. PAR, non-steroidal anti-inflammatory drugs, opioid analgesics and skeletal

muscle relaxants are the main ingredients used in these combination therapies. The binary
M
combination of PAR and CZ gained lots of attention and focus. Analysis of this mixture was

reported using various techniques such as: chemometric spectrophotometry (32-34), RP-HPLC
e d

(35-39), LC-MS/MS (40), packed-column supercritical fluid chromatography (SFC) (41) and
pt

HPTLC (42). In addition, few more specific methods were described dealing with the active
ce

ingredients together with the impurities. Simultaneous determination of PAR, CZ and the related

impurities AP, CA and p-chlorophenol was carried out using HPLC (43). A stability-indicating
Ac

TLC-densitometric method for simultaneous determination of PAR, CZ and their toxic impurities

AP and ACP was published (44). Finally, traditional partial least squares (PLS) and advanced

artificial neural network (ANN) models were applied for the spectrophotometric determination of

both drugs together with their process-related impurities AP, NP, CA, ACP and 4-chlorophenol

(45).
Reviewing the literature exposed that there are no reports on the simultaneous

determination of PAR and CZ in presence of the five cited toxic impurities AP, NP, AT, CA and

ACP. This work introduces the development, validation and application of a simple, specific and

multipurpose HPLC-DAD method for the simultaneous determination of PAR and CZ in bulk

form and in their combined dosage form. The method can be considered stability indicating based

on the fact that AP and ACP are typical degradation products for PAR and CZ respectively.

t
Moreover, separation of 5 potential impurities in a single run demonstrates the impurity profiling

ip
merit of the method.

cr
us
Experimental

Instrumentation
an
The HPLC-DAD system consisted of Agilent 1200 series (Agilent Technologies, Santa
M
Clara, CA, USA) (auto-injector, quaternary pump, vacuum degasser and diode array and multiple
d

wavelength detector G1315 C/D and G1365 C/D) connected to a computer loaded with Agilent
e

ChemStation Software. The column used was Waters Symmetry C8 (3.9 × 150 mm, 5 μm
pt

particle size).
ce

Materials and Chemicals


Ac

PAR was kindly supplied by European Egyptian Pharmaceutical Ind. Co., Alexandria,

Egypt and CZ was kindly donated by Pharco Pharmaceuticals Co., Alexandria, Egypt. The

related substances AP, NP, AT, CA and ACP were purchased from Sigma Aldrich, St. Louis,

MO, USA. HPLC-grade methanol (Fisher Scientific, UK), analytical grade of disodium hydrogen

phosphate anhydrous, ortho-phosphoric acid and high purity distilled water were used. The

pharmaceutical preparation assayed in the study was Relax capsules (AlfaCure


Pharmaceuticals, Badr City, Cairo, Egypt, BN. 17119164) labeled to contain 300 mg PAR and

250 mg CZ per capsule.

General Procedure

A gradient mobile phase system consisting of 0.05 M phosphate buffer pH 7.5 (A) and

methanol (B) was used. The separation was achieved with a linear gradient program as follows: 5

% v/v B at zero time; ramped up to 50% B from 0 to 10 min; then kept constant at 50% B from

t
ip
10 to 20 min. After 20 min, the program was returned to the initial conditions and the analytical

cr
column was reconditioned for 3 min. The flow rate was 1.0 mL/min throughout the run. The

injection volume was 20 L. The eluant was monitored by DAD from 190 to 400 nm, and

us
chromatograms were extracted at the wavelengths 244, 270 and 285 nm. All determinations were

performed at 25ºC.
an
M
PAR (1000 g/mL) and CZ (1000 g/mL) stock solutions were separately prepared in

HPLC-grade methanol. The working standard solutions were prepared by dilution of aliquots of
d

the stock solutions with distilled water to reach the concentration ranges 10-75 and 10-100
e
pt

g/mL for PAR and CZ, respectively. Triplicate injections were made for each concentration and

analyzed under the previously described HPLC conditions. Peak areas were recorded at 244 and
ce

285 nm for PAR and CZ, respectively. The peak areas were plotted against the corresponding
Ac

concentrations to construct the calibration graphs and calculate the regression equations.

Stock solutions of the 5 impurities (1000 g/mL) were separately prepared in HPLC-

grade methanol. Aliquots of the related substances stock solutions were added to aliquots of the

two parent compounds stock solutions, and this mixed solution was diluted to volume with
distilled water. The mixture was chromatographed using the previously described HPLC

conditions and chromatograms were recorded at 270 nm.

Assay of capsules dosage form

The content of 10 capsules were weighed and mixed. An accurately weighed portion of

the powder equivalent to 30 mg PAR and 25 mg CZ was extracted into 10 mL methanol by

shaking for 10 min then filtered into a 25 mL volumetric flask. The residue was washed with 2 ×

t
ip
5 mL portions of methanol and washings were added to the filtrate, then the solution was diluted

to volume with methanol to reach final concentrations of 1200 g/mL for PAR and 1000 g/mL

cr
for CZ. Aliquots of the stock sample solution were diluted with distilled water to obtain final

us
concentrations within the specified ranges and treated as under “General Procedure” and
an
recovered concentrations were calculated from similarly treated external standard solutions.
M
Results and Discussion
d

Optimization and development of the separation method


e
pt

A simple liquid chromatographic method with diode array detection was mainly

developed for routine quality control analysis of PAR/CZ mixture. Another main consideration
ce

during optimization experiments was to make sure that the method is specific and effective
Ac

enough to separate the studied drugs from their toxic impurities. Ideally, complete separation

among all peaks should be within reasonable analysis time to avoid excessive consumption of

solvents and long instrument operation hours. Different experimental conditions were studied and

optimized to achieve the best chromatographic separation among all peaks. For optimization of

the analytical column, a couple of reversed-phase columns were tested: Waters Symmetry C18

(3.9 × 150 mm) and Waters Symmetry C8 (3.9 × 150 mm). The most successful separation
among all the eluting peaks including the five potential impurities was accomplished by the

Waters Symmetry C8 column; therefore, it is the column of choice for this separation.

Various mobile phases were investigated taking into consideration system suitability

parameters. The mobile phase combination of choice was 0.05 M phosphate buffer pH 7.5 and

methanol. Phosphate buffer was substituted by other aqueous phases such as phosphoric acid

solution or water. Additionally, acetonitrile organic modifier was examined either alone or with

t
ip
methanol. In these experiments, insufficient separation or overlapping between some peaks were

cr
observed especially between CA and CZ peaks as well as between ACP and NP peaks. Not only

the composition of the mobile phase was important for separation of this multi-component

us
mixture, but also pH of the phosphate buffer was found crucial for optimum chromatographic
an
separation. Several pH values of the phosphate buffer were tried (pH 4, 5 and 6) where CZ and

CA showed overlapping peaks and almost all the peaks were tailed. Obvious improvement was
M
noticed upon using phosphate buffer pH 7. Baseline separation with resolution value 1.65 was
d

obtained between CZ and CA peaks with better peak shapes. The best separation was achieved at
e

pH 7.5 with resolution values not less than 3.3 among all eluting peaks. Excellent separation,
pt

tolerable peak asymmetry and reasonable retention times were accomplished with gradient
ce

system starting with 5% (by volume) methanol increased linearly to 50% in 10 min, and then

fixed at this % untill the end of the run. Flow rate was kept constant at 1.0 mL/min with the
Ac

temperature of the column adjusted at 25ºC during the run.

Quantitation was achieved using the diode array detection based on peak area

measurement. PAR exhibits an absorption band all over the range 200–300 nm with maximum

absorption at 244 nm. On the other hand, CZ is considered a weak UV absorbing compound at

the previously mentioned wavelength and shows maximum absorption at about 285 nm.
Consequently, 244 and 285 nm were found suitable for recording peak areas of PAR and CZ,

respectively. In addition, the wavelength 270 nm was found suitable for monitoring PAR, CZ and

their toxic impurities simultaneously. The optimized chromatographic conditions showed

excellent separation of the two analytes PAR and CZ together with their studied impurities.

Figure (2) exhibits a typical chromatogram for separation of this complex mixture. The elution

order starts with those of higher polarity AP and PAR, followed by NP, AT, ACP, CZ and finally

t
CA. Their retention times were 3.36, 5.68, 7.99, 10.05, 10.84, 13.46 and 14.40 min respectively.

ip
System suitability parameters were calculated and they were found acceptable (Table 1).

cr
us
Method validation

The validation of the proposed method was accomplished using the validation of analytical
an
procedures of International Conference on Harmonization (ICH) guidelines (46).
M
Concentration ranges, linearity and detection and quantification limits
d

Linearity was accomplished by plotting the measured peak areas at 244 nm and at 285 nm
e

for PAR and CZ, respectively, versus the corresponding concentrations. Table 2 demonstrates the
pt

analytical parameters and data of the proposed method such as concentration ranges, linear
ce

regression equations, correlation coefficients, standard deviations of residuals (Sy/x), standard

deviations of the intercept (Sa) and slope (Sb). Results of the correlation coefficient values
Ac

(0.9998) indicated good linearity with deviation around the slope (Sb%) found to be less than

1%.

Low limit of detection (LOD) and limit of quantification (LOQ) values of PAR and CZ

estimated by the signal-to-noise ratio method (Table 2) confirm the sensitivity of the proposed

method for the determination of the studied drugs.


Accuracy and precision

Three replicate determinations for each concentration of three different concentration levels

for each drug within one day were performed for assessing intra-day precision and accuracy of

the used method. While, for the inter-day precision and accuracy, three replicate determinations

of the same three concentration levels for each drug were determined on three different days. The

obtained recoveries were satisfactory with RSD % and Er % < 2.0 % indicating good precision

t
ip
and accuracy of the proposed method for the determination of PAR and CZ (Table 3).

cr
Specificity

us
The successful separation of PAR and CZ with excellent resolution from their related
an
substances and potential impurities indicated the high specificity of the proposed method (Figure

2). Additionally, the diode-array detection confirmed method’s specificity as it allowed peak
M
purity verification where co-elution of any of the inactive ingredients during assay of the dosage

form was not detected.


e d

Robustness
pt

The effect of small changes in different steps of the procedure was performed in order to
ce

study the robustness of the proposed method. Changes in column temperature (± 5ºC), methanol
Ac

% in the mobile phase (± 2%), flow rate (± 0.05 mL/min) and detection wavelengths (± 2 nm)

were tested. Results obtained showed that such small changes did not cause any significant effect

on peak areas or retention times of all peaks (Table 4). Additionally, these minor experimental

changes did not affect the resolution among eluting peaks. Resolution between any two

successive peaks was never less than 1.99 which implies excellent baseline separation (Table 4).
Stability of solutions

PAR and CZ standard and sample solutions were found to be stable within 6 h at room

temperature without any chromatographic changes observed. Moreover, methanolic solutions of

the studied analytes were stable for at least one week when stored refrigerated at 4ºC except for

AP which was freshly prepared.

t
Assay of capsules dosage forms

ip
The proposed HPLC-DAD method was applied for the determination of PAR and CZ

cr
combination in Relax® capsules pharmaceutical formulation. Figure 3 demonstrates the obtained

us
chromatogram for such dosage form with PAR and CZ eluted at their specific retention times
an
without the appearance of any interfering peaks from the inactive ingredients of the assayed

capsules. Peak purity was assessed by scanning the absorption spectra of each peak at different
M
points in order to assure the absence of co-eluted inactive components (Figure 4). Since they are

superimposable, then the peak is considered pure and homogenous with no signs of co-elution of
e d

any extra substance. Results obtained (Table 5) showed good accuracy and precision with
pt

accepted % recovery, SD and RSD% values. Moreover, determination of PAR and CZ with the
ce

reported HPLC method (43) was applied performed. Statistical comparison using the Student’s t-

and the variance ratio F-tests of the obtained data with those of the proposed method showed that
Ac

the calculated values did not exceed the theoretical ones at the 95% confidence level. Therefore,

no significant differences between the obtained recoveries (Table 5) of the two methods. Thus,

the proposed method is applicable to the assay of the binary mixture of PAR and CZ in capsules

dosage form with satisfactory level of precision and accuracy.


Conclusion

A simple, specific and rapid gradient elution HPLC procedure for the assay of PAR and

CZ in their pharmaceutical formulation is described in this work. Water was used as a solvent

with the minimum requirement of organic solvents during preparation of most of the solutions

used. This promotes the developed method to be environment-friendly, simple and cost-effective.

Moreover, the single step of changing the mobile phase composition linearly with keeping the

t
ip
flow rate constant adds to the method simplicity. Upon comparison with other reported methods

cr
(32-45) for the analysis of PAR-CZ mixture, the developed method showed better specificity for

us
the determination of such combination, in addition to the separation of the two drugs from five of

their toxic impurities and reported degradation products. Therefore, the proposed method can be
an
applied for stability indicating assay and impurity profiling purposes. Also, using DAD allows
M
peak identity and purity confirmation which imparts the proposed method an additional

advantage over methods that use the universal UV detector. Reliability of the proposed method
d

was assured by examining different validation parameters and the successful application to
e

capsules formulation.
pt
ce

The authors have declared no conflicts of interest.


Ac
References

1- Bosch, M.E., Sánchez, A.J.R., Rojas, F.S., Ojeda, C.B. Determination of paracetamol:

Historical evolution (2006) Journal of Pharmaceutical and Biomedical Analysis, 42 (3), 291-321.

2- The British Pharmacopoeia, Her Majesty’s Stationary Office, London, Volume II, 502-503

(2016).

3- European Pharmacopoeia, Fifth Edition, Volume II, 2184-2185 (2005).

t
ip
4- Adegoke, O.A., Thomas, O.E., Amao, S.A., Agboola, S.O., Omotosho, A.E. A new method

cr
for the microdetermination of Para-aminophenol in generic brands of paracetamol tablets (2019)

Arab Journal of Basic and Applied Sciences, 26 (1), 153-162.

us
5- Abdelwahab, N.S., Abdelrahman, M.M., Boshra, J.M., Taha, A.A. Different stability-
an
indicating chromatographic methods for specific determination of paracetamol, dantrolene

sodium, their toxic impurities and degradation products (2019) Biomedical Chromatography, 33
M
(9), art. no. e4598.
d

6- Thirumalraj, B., Rajkumar, C., Chen, S.-M., Lin, K.-Y. Determination of 4-nitrophenol in
e

water by use of a screen-printed carbon electrode modified with chitosan-crafted ZnO


pt

nanoneedles (2017) Journal of Colloid and Interface Science, 499, 83-92.


ce

7- Brune, K., Renner, B., Tiegs, G. Acetaminophen/paracetamol: A history of errors, failures and

false decisions (2015) European Journal of Pain (United Kingdom), 19 (7), 953-965.
Ac

8- Kumar, S.P., Giribabu, K., Manigandan, R., Munusamy, S., Muthamizh, S., Padmanaban, A.,

Dhanasekaran, T., Suresh, R., Narayanan, V. Simultaneous determination of paracetamol and 4-

aminophenol based on poly(chromium Schiff base complex) modified electrode at nanomolar

levels (2016) Electrochimica Acta, 194, 116-126.


9- Wang, H., Zhang, S., Li, S., Qu, J. Electrochemical sensor based on palladium-reduced

graphene oxide modified with gold nanoparticles for simultaneous determination of

acetaminophen and 4-aminophenol (2018) Talanta, 178, 188-194.

10- Almandil, N.B., Ibrahim, M., Ibrahim, H., Kawde, A.-N., Shehatta, I., Akhtar, S. A hybrid

nanocomposite of CeO2-ZnO-chitosan as an enhanced sensing platform for highly sensitive

voltammetric determination of paracetamol and its degradation product: p-aminophenol (2019)

t
RSC Advances, 9 (28), 15986-15996.

ip
11- Wang, J., Zhang, H., Zhao, J., Zhang, R., Zhao, N., Ren, H., Li, Y. Simultaneous

cr
determination of paracetamol and p-aminophenol using glassy carbon electrode modified with

us
nitrogen- and sulfur- co-doped carbon dots (2019) Microchimica Acta, 186 (11), art. no. 733.
an
12- Filik, H., Hayvali, M., Kilic, E. Sequential spectrophotometric determination of paracetamol

and p-aminophenol with 2,2′-(1,4-phenylenedivinylene) bis-8-hydroxyquinoline as a novel


M
coupling reagent after microwave assisted hydrolysis (2005) Analytica Chimica Acta, 535 (1-2),

177-182.
e d

13- Khodaveisi, J., Dadfarnia, S., Haji Shabani, A.M., Rohani Moghadam, M., Hormozi-Nezhad,
pt

M.R. Artificial neural network assisted kinetic spectrophotometric technique for simultaneous
ce

determination of paracetamol and p-aminophenol in pharmaceutical samples using localized

surface plasmon resonance band of silver nanoparticles (2015) Spectrochimica Acta - Part A:
Ac

Molecular and Biomolecular Spectroscopy, 138, 474-480.

14- Eldin, A.B., Ismaiel, O.A., Hassan, W., Shalaby, A. Comparison of FT-NIR transmission and

hplc for green approach to determine paracetamol and its degradation product 4-aminophenol in

paracetamol tablets (2015) International Journal of Pharmacy and Pharmaceutical Sciences, 7 (7),

384-389.
15- Santos, L.H.M.L.M., Paíga, P., Araújo, A.N., Pena, A., Delerue-Matos, C., Montenegro,

M.C.B.S.M. Development of a simple analytical method for the simultaneous determination of

paracetamol, paracetamol-glucuronide and p-aminophenol in river water (2013) Journal of

Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 930, 75-81.

16- Khan, H., Ali, M., Ahmad, S., Ahmad, N., Ahuja, A., Baboota, S., Ali, J. Validated UPLC/Q-

TOF-MS method for simultaneous determination of aceclofenac, paracetamol, and their

t
degradation products in tablets (2012) Journal of Liquid Chromatography and Related

ip
Technologies, 35 (1), 109-128.

cr
17- Abdelwahab, N.S., Abdelaleem, E.A., Abdelrahman, M.M. HPTLC-Densitometric Method

us
for Determination of Ascorbic Acid, Paracetamol and Guaifenesin in Presence of Their Toxic
an
Impurities (2019) Journal of Chromatographic Science, 57 (2), 149-155.

18- Németh, T., Jankovics, P., Németh-Palotás, J., Koszegi-Szalai, H. Determination of


M
paracetamol and its main impurity 4-aminophenol in analgesic preparations by micellar

electrokinetic chromatography (2008) Journal of Pharmaceutical and Biomedical Analysis, 47 (4-


e d

5), 746-749.
pt

19- Chu, Q., Jiang, L., Tian, X., Ye, J. Rapid determination of acetaminophen and p-aminophenol
ce

in pharmaceutical formulations using miniaturized capillary electrophoresis with amperometric

detection (2008) Analytica Chimica Acta, 606 (2), 246-251.


Ac

20- Rao, R.N., Narasaraju, A. Rapid separation and determination of process-related substances

of paracetamol using reversed-phase HPLC with photo diode array as a detector (2006)

Analytical Sciences, 22 (2), 287-292.

21- Vojta, J., Hanzlík, P., Jedlička, A., Coufal, P. Separation and determination of impurities in

paracetamol, codeine and pitophenone in the presence of fenpiverinium in combined suppository

dosage form (2015) Journal of Pharmaceutical and Biomedical Analysis, 102, 85-92.
22- Zheng, Y., Peng, Q., Dong, R., Chen, T., Bao, Y., Peng, Q., Yang, M. Simultaneous

determination of methocarbamol and paracetamol in the presence of three related substances by

ultra performance liquid chromatography (2019) Current Pharmaceutical Analysis, 15 (5), 505-

510.

23- Belal, T., Awad, T., Clark, C.R. Stability-indicating simultaneous determination of

paracetamol and three of its related substances using a direct GC/MS method (2009) Journal of

t
AOAC International, 92 (6), 1622-1630.

ip
24- Sweetman, S. C., Martindale, The Complete Drug Reference, 36th edition, Pharmaceutical

cr
Press, London, UK, 1894-1895 (2009).

us
25- Ellaithy, M.M., El-Ragehy, N.A., El-Ghobashy, M.A. Kinetic study of alkaline induced
an
hydrolysis of the skeletal muscle relaxant chlorzoxazone using ratio spectra first derivative

spectrophotometry (2003) Farmaco, 58 (4), 337-342.


M
26- Abdelrahman, M.M., Abdelwahab, N.S., Taha, A.A., Boshra, J.M. Determination of

chlorzoxazone, diclofenac potassium, and chlorzoxazone toxic degradation product by different


e d

chromatographic methods (2016) Journal of Planar Chromatography - Modern TLC, 29 (6), 453-
pt

461.
ce

27- Yamazaki, K., Suzuki, M., Kano, H., Umeda, Y., Matsumoto, M., Asakura, M., Nagano, K.,

Arito, H., Fukushima, S. Oral carcinogenicity and toxicity of 2-amino-4-chlorophenol in rats


Ac

(2009) Journal of Occupational Health, 51 (3), 249-260.

28- Ahmed, H.M., Elshamy, Y.S., Talaat, W., Labib, H.F., Belal, T.S. Simultaneous analysis of

chlorzoxazone, diclofenac sodium and tramadol hydrochloride in presence of three potential

impurities using validated HPLC-DAD and HPTLC methods (2020) Microchemical Journal, 153,

art. no. 104505.


29- Elkady, E.F., Fouad, M.A. Two liquid chromatographic methods for the simultaneous

determination of ibuprofen and methocarbamol or chlorzoxazone in the presence of their

degradation products (2012) Journal of Liquid Chromatography and Related Technologies, 35

(7), 882-895.

30- Hassib, S.T., Mohammad, A.-A., El-Zaher, A.A., El-Kady, E.F. Simultaneous determination

of chlorzoxazone and ketoprofen in binary mixtures and in ternary mixtures containing the

t
chlorzoxazone degradation product by reversed-phase liquid chromatography (2007) Journal of

ip
AOAC International, 90 (3), 693-699.

cr
31- El Bayoumi, A.A., Amer, S.M., Moustafa, N.M., Tawakkol, M.S. Spectrodensitometric

us
determination of clorazepate dipotassium, primidone and chlorzoxazone each in presence of its
an
degradation product (1999) Journal of Pharmaceutical and Biomedical Analysis, 20 (5), 727-735.

32- Wahbi, A.-A.M., Gazy, A.A., Abdel-Razak, O., Mahgoub, H., Moneeb, M.S. Simultaneous
M
determination of paracetamol and chlorzoxazone using orthogonal functions-ratio

spectrophotometry (2003) Saudi Pharmaceutical Journal, 11 (4), 192-200.


e d

33- Toubar, S.S., Hegazy, M.A., Elshahed, M.S., Helmy, M.I. Novel pure component
pt

contribution, mean centering of ratio spectra and factor based algorithms for simultaneous
ce

resolution and quantification of overlapped spectral signals: An application to recently co-

formulated tablets of chlorzoxazone, aceclofenac and paracetamol (2016) Spectrochimica Acta -


Ac

Part A: Molecular and Biomolecular Spectroscopy, 163, 89-95.

34- El-Bagary, R.I., El-Kady, E.F., Al-Matari, A.A. Simultaneous spectrophotometric

determination of diclofenac sodium, paracetamol, and chlorzoxazone in ternary mixture using

chemometric and artificial neural networks techniques (2017) Asian Journal of Pharmaceutical

and Clinical Research, 10 (11), 225-230.


35- Dinç, E., Ozdemir, A., Aksoy, H., Baleanu, D. Chemometric approach to simultaneous

chromatographic determination of paracetamol and chlorzoxazone in tablets and spiked human

plasma (2006) Journal of Liquid Chromatography and Related Technologies, 29 (12), 1803-1822.

36- Joshi, R., Sharma, R. Development and validation of RP-HPLC method for simultaneous

estimation of three-component tablet formulation containing acetaminophen, chlorzoxazone, and

aceclofenac (2008) Analytical Letters, 41 (18), 3297-3308.

t
37- Shaikh, K.A., Devkhile, A.B. Simultaneous determination of aceclofenac, paracetamol, and

ip
chlorzoxazone by RP-HPLC in pharmaceutical dosage form (2008) Journal of Chromatographic

cr
Science, 46 (7), 649-652.

us
38- Badgujar, M.A., Pingale, S.G., Mangaonkar, K.V. Simultaneous determination of
an
paracetamol, chlorzoxazone and diclofenac sodium in tablet dosage form by high performance

liquid chromatography (2011) E-Journal of Chemistry, 8 (3), 1206-1211.


M
39- Salih, M.E., Aqel, A., Abdulkhair, B.Y., Alothman, Z.A., Abdulaziz, M.A., Yacine Badjah-

Hadj-Ahmed, A. Simultaneous determination of paracetamol and chlorzoxazone in their


e d

combined pharmaceutical formulations by reversed-phase capillary liquid chromatography using


pt

a polymethacrylate monolithic column (2018) Journal of Chromatographic Science, 56 (9), 819-


ce

827.

40- Mohamed, D., Hegazy, M.A., Elshahed, M.S., Toubar, S.S., Helmy, M.I. Liquid
Ac

chromatography–tandem MS/MS method for simultaneous quantification of paracetamol,

chlorzoxazone and aceclofenac in human plasma: An application to a clinical pharmacokinetic

study (2018) Biomedical Chromatography, 32 (7), art. no. e4232.

41- Desai, P.P., Patel, N.R., Sherikar, O.D., Mehta, P.J. Development and validation of packed

column supercritical fluid chromatographic technique for quantification of chlorzoxazone,


paracetamol and aceclofenac in their individual and combined dosage forms (2012) Journal of

Chromatographic Science, 50 (9), 769-774.

42- Mohite, V.I., Potawale, S.E., Gabhe, S.Y. Development and validation of HPTLC method for

simultaneous estimation of paracetamol, diclofenac potassium and chlorzoxazone in bulk drug

and tablet dosage form (2013) International Journal of Pharmacy and Pharmaceutical Sciences, 5

(2), 432-435.

t
43- Ali, M.S., Rafiuddin, S., Ghori, M., Kahtri, A.R. Simultaneous determination of paracetamol,

ip
chlorzoxazone, and related impurities 4-aminophenol, 4′-chloroacetanilide, and p-chlorophenol in

cr
pharmaceutical preparations by high-performance liquid chromatography (2007) Journal of

us
AOAC International, 90 (1), 82-93.
an
44- Abdelaleem, E.A., Abdelwahab, N.S. Stability-indicating TLC-densitometric method for

simultaneous determination of paracetamol and chlorzoxazone and their toxic impurities (2013)
M
Journal of Chromatographic Science, 51 (2), 187-191.

45- Saad, A.S., AlAlamein, A.M.A., Galal, M.M., Zaazaa, H.E. Traditional versus advanced
e d

chemometric models for the impurity profiling of paracetamol and chlorzoxazone: Application to
pt

pure and pharmaceutical dosage forms (2018) Spectrochimica Acta - Part A: Molecular and
ce

Biomolecular Spectroscopy, 205, 376-380.

46- ICH, Validation of Analytical Procedures: Text and Methodology, Q2(R1), International
Ac

Conference on Harmonisation, November 2005.


PAR CZ AP

t
ip
cr
us
an
M
e d
pt

ACP AT CA NP
ce

Figure 1: Structures of paracetamol (PAR), chlorzoxazone (CZ), 4-aminophenol (AP), 4-


nitrophenol (NP), acetanilide (AT), 4-chloroacetanilide (CA) and 2-amino-4-chlorophenol
Ac

(ACP).
DAD1E,Sig=270,4Ref=off,TT(KARIN1-11-2017\MIX-3-PH7500003.D)
mAU
2
140 3
120 6
100

80
7
4
5

t
60
1

ip
40

cr
20

us
0 2 4 6 8 10 12 14 16 18 min
Figure 2: HPLC chromatogram at 270 nm for a mixture containing 50 g/mL of each of (1) 4-
aminophenol (AP), (2) paracetamol (PAR), (3) 4-nitrophenol (NP), (4) acetanilide (AT), (5) 2-
an
amino-4-chlorophenol (ACP), (6) chlorzoxazone (CZ) and (7) 4-chloroacetanilide (CA)
M
e d
pt
ce
Ac
DAD1A, Sig=244,4Ref=off, TT(KARIN6-11-2017\C2-60PAR-50CZ30.D)
mAU
PAR A
400

350

300

250

200

t
150

ip
100

cr
50

us
0

0 2 4 6 8 10 12 14 16 18 min
DAD1B, Sig=285,4Ref=off, TT(KARIN6-11-2017\C2-60PAR-50CZ30.D)
mAU
an CZ B
120
M
100

PAR
80
d

60
e
pt

40
ce

20

0
Ac

0 2 4 6 8 10 12 14 16 18 min

Figure 3: HPLC chromatograms at 244 nm (A) and 285 nm (B) of a solution containing 60
µg/mL PAR and 50 g/mL CZ obtained from Relax® capsules.
*DAD1,5.651(110Fl,-)Ref=5.477&6.624of C2-60PAR-50CZ30.D
*DAD1,5.691(390Fl,-)Ref=5.477&6.624of C2-60PAR-50CZ30.D A
*DAD1,5.724(548Fl,-)Ref=5.477&6.624of C2-60PAR-50CZ30.D
*DAD1,5.784(411Fl,-)Ref=5.477&6.624of C2-60PAR-50CZ30.D
*DAD1,5.851(175Fl,-)Ref=5.477&6.624of C2-60PAR-50CZ30.D
Norm.
500

400

300

t
200

ip
100

cr
0
220 240 260 280 300 320 340 360 380 nm

us
*DAD1,13.457(198Fl,-)Ref=13.244&14.471of C2-60PAR-50CZ30.D
*DAD1,13.504(523Fl,-)Ref=13.244&14.471of C2-60PAR-50CZ30.D B
*DAD1,13.551(711Fl,-)Ref=13.244&14.471of C2-60PAR-50CZ30.D
*DAD1,13.644(497Fl,-)Ref=13.244&14.471of C2-60PAR-50CZ30.D
an
*DAD1,13.751(257Fl,-)Ref=13.244&14.471of C2-60PAR-50CZ30.D
Norm.
M
600
500
d

400
e

300
pt

200
100
ce

0
220 240 260 280 300 320 340 360 380 nm
Ac

Figure 4: Purity plots for 60 μg/mL PAR (A) and 50 μg/mL CZ (B) obtained from analysis of
Relax® capsules.
Table 1: System suitability parameters for the separated compounds in this study
%RSD
Capacity Theoretical
Tailing Selectivity Resolution of
Compound tR ± SD (min) factor Plates
Factor () (Rs) Peak
(k) (N)
Area
AP 03.36 ± 0.004 1.24 03295 1.08 0.11
PAR 05.68 ± 0.003 2.79 15746 1.08 1.69 11.18 0.10
NP 07.99 ± 0.018 4.31 20469 1.04 1.40 11.30 1.29

t
ip
AT 10.05 ± 0.007 5.70 33705 1.17 1.26 09.42 0.21
ACP 10.84 ± 0.006 6.23 37916 1.21 1.08 03.58 0.67

cr
CZ 13.46 ± 0.006 7.97 43633 1.14 1.24 10.86 0.54
CA 14.40 ± 0.012 8.61 33030 1.15 1.07 03.31 1.15

us
an
M
e d
pt
ce
Ac
Table 2: Analytical parameters for the determination of PAR-CZ mixture using the proposed
HPLC-DAD method

Parameter PAR CZ

Concentration range (μg/mL) 10 – 75 10 – 100


Intercept (a) –7.745 14.019
S aa 17.795 13.174
Slope (b) 63.805 36.749

t
ip
Sbb 0.413 0.240
RSD% of the slope (Sb%) 0.647 0.653

cr
Correlation coefficient (r) 0.99991 0.99989

us
Sy/xc 21.424 18.630
LODe (μg/mL) 1.191 1.705
f an
LOQ (μg/mL) 3.968 5.685
M
e d
pt
ce
Ac
Table 3: Precision and accuracy for the analysis of PAR and CZ in bulk form using the proposed
HPLC-DAD method.
Nominal value Found ± SDa
RSD(%)b Er(%)c
(μg/mL) (μg/mL)

20 20.06 ± 0.057 0.280 -0.30


Within-day 50 50.07 ± 0.085 0.170 -0.14
75 74.91 ± 0.041 0.050 –0.12
PAR
20 19.89 ± 0.028 0.140 –0.55

t
ip
Between-day 50 50.06 ± 0.349 0.700 -0.12
75 75.02 ± 0.671 0.890 -0.03

cr
20 19.99 ± 0.114 0.570 –0.05

us
Within-day 50 50.01 ± 0.002 0.004 -0.02
75 74.77 ± 0.048 0.060 –0.31
CZ an
20 20.30 ± 0.112 0.550 -1.50
Between-day 50 50.61 ± 0.869 1.720 -1.22
M
75 74.85 ± 1.399 1.870 –0.20

a
Mean ± standard deviation for three determinations.
d

b
% Relative standard deviation.
c
e

% Relative error.
pt
ce
Ac
Table 4: Evaluation of robustness of the proposed HPLC-DAD method.
Peak area ± SD
Retention Resolution RSD
Parameter Compound PAR at 244 nm and
time ± SD (Rs ± SD) %
CZ at 285 nm
AP 03.35 ± 0.336
Methanol PAR 05.68 ± 0.418 09.26 ± 0.495 3322.13 ± 8.21 0.25
percentage NP 08.52 ± 0.427 11.59 ± 0.123
in the mobile AT 10.06 ± 0.436 05.90 ± 0.046
phase ACP 10.83 ± 0.426 02.94 ± 0.051
± 2% CZ 13.71 ± 0.655 10.07 ± 0.218 1919.40 ± 10.62 0.55
CA 14.42 ± 0.755 02.06 ± 0.050

t
AP 03.34 ± 0.147

ip
PAR 05.69 ± 0.201 09.28 ± 0.075 3291.43 ± 86.23 2.62
NP 08.53 ± 0.248 11.59 ± 0.064

cr
Flow rate
AT 10.07 ± 0.254 05.85 ± 0.120
± 0.05
ACP 10.84 ± 0.257 0 2.92 ± 0.056
mL/min

us
CZ 13.68 ± 0.297 09.95 ± 0.235 1893.31 ± 19.72 1.04
CA 14.39 ± 0.342 02.05 ± 0.035
AP 03.34 ± 0.143
PAR
NP
05.69 ± 0.248
08.53 ± 0.485
an
09.21 ± 0.533
11.36 ± 0.741
3329.17 ± 23.31 0.70
Column
AT 10.06 ± 0.301 05.73 ± 0.822
temperature
M
ACP 10.83 ± 0.331 02.86 ± 0.087
± 5 °C
CZ 13.69 ± 0.496 09.77 ± 0.187 1919.34 ± 36.95 1.93
CA 14.40 ± 0.529 01.99 ± 0.124
d

Working
PAR 3382.57 ± 112.24 3.32
e

wavelength
CZ 1892.06 ± 23.06 1.22
± 2 nm
pt
ce
Ac
Table 5: Application of the proposed HPLC-DAD method to the analysis of PAR-CZ mixture in
capsules dosage form (Relax capsules).
Proposed method Reference method
Parameters (HPLC Method)
PAR CZ PAR CZ
%Recovery ± SDa 100.12 ± 0.68 99.72 ± 0.20 99.84 ± 1.07 99.31 ± 0.44
RSD%b 0.68 0.20 1.07 0.44
t 0.48 1.93
F 2.48 4.84

t
a

ip
Mean ± standard deviation for five determinations.
b
% Relative standard deviation.
Theoretical values for t and F at p = 0.05 are 2.31 and 6.39, respectively.

cr
us
an
M
e d
pt
ce
Ac

You might also like